Verge Genomics is using machine learning and human genomics to accelerate drug discovery. Technology has the potential to revolutionize drug discovery by making the process cheaper and faster. Verge is capitalizing on this with their ConVERGE platform, which uses machine learning to map the complex causes of disease from their proprietary multi-omics database. Once the cause of disease has been identified, Verge uses their internal biology and chemistry platforms to select proprietary drug candidates that have high probability of clinical success. Verge’s first drug candidate for ALS treatment is expected to enter clinical trials in 2022. Their remaining portfolio includes drug development for Parkinson’s disease and Frontotemporal Dementia patients.